Coloplast upgrades growth expectations following acquisition
Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.
by christopher due karlsson, translated by daniel pedersen
On Tuesday, Coloplast upgraded its forecasted reported revenue growth in Danish kroner, the medtech company announces in its first quarterly report for financial year 2021/2022.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
